Imagen de Portada

Characterizing second line and beyond therapies for primary central nervous system lymphomas

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Brian Primeaux, Chelsea Luo, Erin K. Yeung, Caitlin Linger, Sheree Chen, Bryan Do
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Hematological Oncology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
por: Maria Anele Romeo, et al.
Publicado: (2024)

The role of baseline 2‐[ 18 F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis
por: Domenico Albano, et al.
Publicado: (2024)

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
por: Kaitlin Annunzio, et al.
Publicado: (2024)

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD
por: Carmen Martínez, et al.
Publicado: (2024)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
por: Hidehiro Itonaga, et al.
Publicado: (2024)

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
por: Evgenia Verrou, et al.
Publicado: (2024)

Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan
por: Kenji Ishitsuka, et al.
Publicado: (2024)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
por: Beatrice Casadei, et al.
Publicado: (2024)

Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition
por: João L. Pereira, et al.
Publicado: (2024)

Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203
por: Takashi Watanabe, et al.
Publicado: (2024)

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
por: Jiangfang Feng, et al.
Publicado: (2024)

Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
por: Taku Kikuchi, et al.
Publicado: (2024)

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes
por: Xiaohui Wang, et al.
Publicado: (2024)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
por: Elisabetta M. Abenavoli, et al.
Publicado: (2024)

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
por: Antonio Pinto, et al.
Publicado: (2024)

Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
por: Mohammed Zuber, et al.
Publicado: (2024)

Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation
por: José Carlos Jaime‐Pérez, et al.
Publicado: (2024)

Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis
por: Maria Livia Del Giudice, et al.
Publicado: (2024)

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
por: Caroline Le Lan, et al.
Publicado: (2024)

Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
por: Vittorio Ruggero Zilioli, et al.
Publicado: (2024)

Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems
por: Yu‐Sung Chang, et al.
Publicado: (2025)

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
por: Michèle Hoffmann, et al.
Publicado: (2025)

631 | EFFICACY OF POLA‐R‐CHP IN PREVIOUSLY UNTREATED CD5‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA
por: J. Sui, et al.
Publicado: (2025)

555 | ADVERSE EVENTS OF INTEREST WITH ZANUBRUTINIB VERSUS FIXED‐DURATION COMBINATION OF VENETOCLAX + OBINUTUZUMAB IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA
por: N. Lamanna, et al.
Publicado: (2025)

618 | SEQUENTIAL BTK INHIBITOR THERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: REAL‐WORLD OUTCOMES AND ATTRITION RATES—FINAL REPORT FROM THE ASIA‐PACIFIC REGISTRY
por: H. Cho, et al.
Publicado: (2025)

867 | A NOVEL TREATMENT REGIMEN FOR NEWLY DIAGNOSED CAEBV INDUCING A HIGH RESPONSE RATE: PD‐1 INHIBITOR, L‐ASPARGASE AND CHIDAMIDE
por: Y. Di, et al.
Publicado: (2025)

443 | A PHASE 1 STUDY OF PRT2527, A SELECTIVE CDK9 INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES: UPDATED ANALYSIS
por: W. Jurczak, et al.
Publicado: (2025)

549 | PROSPECTIVE PATIENT PREFERENCE STUDY FOR CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT ATTRIBUTES IMPACTING PATIENT SHARED‐DECISION MAKING
por: S. Ailawadhi, et al.
Publicado: (2025)

445 | ELA026, A MONOCLONAL ANTIBODY TARGETING SIRP‐EXPRESSING MYELOID CELLS AND T LYMPHOCYTES, DEMONSTRATES BROAD ANTI‐TUMOR ACTIVITY IN PATIENTS WITH LYMPHOMA
por: S. Iyer, et al.
Publicado: (2025)

106 | LYL314, A CD19/CD20 CAR T‐CELL CANDIDATE ENRICHED FOR CD62L+ STEM‐LIKE CELLS, ACHIEVES HIGH RATES OF DURABLE COMPLETE RESPONSES IN R/R LARGE B‐CELL LYMPHOMA
por: A. Merchant, et al.
Publicado: (2025)

514 | CAN BASELINE 18F‐FDG PET/CT PREDICT THE PROGNOSIS OF PRIMARY CNS LYMPHOMA?
por: H. Zhu, et al.
Publicado: (2025)

763 | CD4+ CADM1+ T CELL POPULATION EMERGES AS A MALIGNANCY‐ASSOCIATED BIOMARKER IN EBV‐RELATED LYMPHOPROLIFERATIVE DISORDERS
por: Q. Luo, et al.
Publicado: (2025)

453 | EFFICACY AND TOXICITY OF RADIATION THERAPY PRIOR TO CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: K. Daniels, et al.
Publicado: (2025)

Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
por: Mariarita Sciumè, et al.
Publicado: (2024)

528 | DETECTION OF RECURRENT GENOMIC ALTERATIONS AND MINIMAL RESIDUAL DISEASE WITH CELL‐FREE DNA AND BONE MARROW IN WALDENSTRÖM’S MACROGLOBULINEMIA.
por: S. Chow, et al.
Publicado: (2025)

231 | IMPACT OF RITUXIMAB EARLY ADMINISTRATION ON OUTCOMES IN ADVANCED STAGE LOW TUMOR BURDEN FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF PHASE III JCOG1411/FLORA STUDY
por: D. Maruyama, et al.
Publicado: (2025)

563 | PATIENT PREFERENCES FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN THE NOVEL TREATMENT ERA: INTERIM SURVEY RESULTS
por: K. Patel, et al.
Publicado: (2025)

553 | DIGITAL TECHNOLOGY AND NATURAL LANGUAGE PROCESSING IN ACTION: EXPLORING THE BELGIAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT POPULATION WITH THE BE‐CLLEAR STUDY
por: M. Vanderkerken, et al.
Publicado: (2025)

163 | TAZEMETOSTAT PLUS AMDIZALISIB IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA PATIENTS WITH DIVERSE GENOMIC SIGNATURES: RESULTS FROM A PHASE 2 STUDY
por: S. Cheng, et al.
Publicado: (2025)

878 | DEVELOPING AN OUTPATIENT BISPECIFIC ANTIBODY THERAPY PROGRAM: INFRASTRUCTURE AND TOOLS FROM THE JOHNS HOPKINS SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER
por: N. Shafagati, et al.
Publicado: (2025)